Use of ajmaline in patients with the Wolff-Parkinson-White syndrome to disclose short refractory period of the accessory pathway

Am J Cardiol. 1980 Jan;45(1):130-3. doi: 10.1016/0002-9149(80)90230-1.

Abstract

Ajmaline given intravenously produced complete anterograde block in the accessory pathway of 32 of 59 patients with the Wolff-Parkinson-White syndrome. An electrophysiologic investigation performed 1 day later revealed that failure of ajmaline to produce complete anterograde block in the accessory pathway corresponded to a short refractory period of this pathway (less than 270 ms). The use of ajmaline intravenously is advanced as a reliable and rapid procedure for identifying those patients with the Wolff-Parkinson-White syndrome who have a short refractory period of the accessory pathway and are possible at risk of circulatory insufficiency or sudden death if atrial fibrillation supervenes.

MeSH terms

  • Adolescent
  • Adult
  • Ajmaline* / adverse effects
  • Atrial Fibrillation / diagnosis
  • Atrial Fibrillation / mortality
  • Child
  • Electrophysiology
  • Female
  • Humans
  • Male
  • Middle Aged
  • Time Factors
  • Wolff-Parkinson-White Syndrome / diagnosis*

Substances

  • Ajmaline